A detailed history of Woodline Partners LP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 104,831 shares of SAGE stock, worth $1.11 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
104,831
Holding current value
$1.11 Million
% of portfolio
0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$18.62 - $26.95 $1.95 Million - $2.83 Million
104,831 New
104,831 $1.96 Million
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $2.14 Million - $2.96 Million
-77,866 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$30.71 - $45.71 $2.39 Million - $3.56 Million
77,866 New
77,866 $2.58 Million
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $1.29 Million - $1.64 Million
-34,813 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $1.4 Million - $2 Million
34,813 New
34,813 $1.54 Million
Q2 2021

Aug 16, 2021

SELL
$54.88 - $79.29 $12.9 Million - $18.6 Million
-234,434 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$70.65 - $96.76 $3.52 Million - $4.83 Million
49,876 Added 27.02%
234,434 $17.5 Million
Q4 2020

Feb 16, 2021

SELL
$58.41 - $89.06 $33,644 - $51,298
-576 Reduced 0.31%
184,558 $16 Million
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $4.23 Million - $6.42 Million
-102,809 Reduced 35.7%
185,134 $11.3 Million
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $3.35 Million - $5.57 Million
129,116 Added 81.29%
287,943 $12 Million
Q1 2020

May 15, 2020

BUY
$26.15 - $77.24 $3.62 Million - $10.7 Million
138,535 Added 682.71%
158,827 $4.56 Million
Q4 2019

Feb 14, 2020

BUY
$60.18 - $154.77 $1.22 Million - $3.14 Million
20,292 New
20,292 $1.47 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $631M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.